{"id":44992,"date":"2022-06-13T12:01:37","date_gmt":"2022-06-13T10:01:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/"},"modified":"2022-06-13T12:01:37","modified_gmt":"2022-06-13T10:01:37","slug":"global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/","title":{"rendered":"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/2336340\/global_cancer_monoclonal_antibody_partnering?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=rdfxbg&amp;utm_campaign=1712479+-+Global+Cancer+Monoclonal+Antibody+Partnering+Terms+and+Agreements+2015-2022%3A+Disclosed+Headlines%2C+Upfronts%2C+Milestones+and+Royalties+by+Stage+of+Development&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220613005430\/en\/1484234\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220613005430\/en\/1484234\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe Cancer Monoclonal Antibody Partnering Terms &amp; Agreements report provides comprehensive access to available deals and contract documents for over 600 cancer monoclonal antibody deals entered into by the worlds leading healthcare companies.\n<\/p>\n<p>\n<strong>This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:<\/strong>\n<\/p>\n<ul>\n<li>\nMonoclonal antibodies\n<\/li>\n<li>\nMurine mAb\n<\/li>\n<li>\nChimeric mAb\n<\/li>\n<li>\nHumanized mAb\n<\/li>\n<li>\nHuman aAb\n<\/li>\n<\/ul>\n<p>\nUnderstanding the flexibility of a prospective partner&#8217;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &#8211; contract documents provide this insight where press releases and databases do not.\n<\/p>\n<p>\nThis report contains a comprehensive listing of all cancer monoclonal antibody partnering deals announced since Jan 2015, including financial terms where available, including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.\n<\/p>\n<p>\nThe initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.\n<\/p>\n<p>\nChapter 3 provides a review of the leading cancer monoclonal antibody deals since 2015. Deals are listed by headline value, signed by big pharma, most active cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\n<\/p>\n<p>\nChapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.\n<\/p>\n<p>\nChapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&amp;D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\n<\/p>\n<p>\nChapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2015. The chapter is organized by specific cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\n<\/p>\n<p>\nIn addition, a comprehensive appendix is provided organized by cancer monoclonal antibody partnering company A-Z, deal type definitions and cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\n<\/p>\n<p>\nThe report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2015.\n<\/p>\n<p>\nIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.\n<\/p>\n<p>\n<strong>Key benefits<\/strong>\n<\/p>\n<p>\n<strong>Global Cancer Monoclonal Antibody Partnering Terms &amp; Agreements provides the reader with the following key benefits:<\/strong>\n<\/p>\n<ul>\n<li>\nIn-depth understanding of cancer monoclonal antibody deal trends since 2015\n<\/li>\n<li>\nAccess to headline, upfront, milestone and royalty data\n<\/li>\n<li>\nComprehensive access to over 600 actual cancer monoclonal antibody deals entered into by the world&#8217;s biopharma companies\n<\/li>\n<li>\nIdentify most active companies in cancer monoclonal antibody partnering\n<\/li>\n<li>\nInsight into the terms included in a cancer monoclonal antibody agreement\n<\/li>\n<li>\nUnderstand the key deal terms companies have agreed in previous deals\n<\/li>\n<li>\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\n<\/li>\n<li>\nSpot the emerging companies in the cancer monoclonal antibody area\n<\/li>\n<\/ul>\n<p>\n<strong>Available deals are listed by:<\/strong>\n<\/p>\n<ul>\n<li>\nCompany A-Z\n<\/li>\n<li>\nHeadline value\n<\/li>\n<li>\nStage of development at signing\n<\/li>\n<li>\nDeal component type\n<\/li>\n<li>\nSpecific oncology therapy target\n<\/li>\n<li>\nMonoclonal antibody type\n<\/li>\n<\/ul>\n<p>\n<strong>Analyzing actual contract agreements allows assessment of the following:<\/strong>\n<\/p>\n<ul>\n<li>\nWhat are the precise rights granted or optioned?\n<\/li>\n<li>\nWhat is actually granted by the agreement to the partner company?\n<\/li>\n<li>\nWhat exclusivity is granted?\n<\/li>\n<li>\nWhat is the payment structure for the deal?\n<\/li>\n<li>\nHow are sales and payments audited?\n<\/li>\n<li>\nWhat is the deal term?\n<\/li>\n<li>\nHow are the key terms of the agreement defined?\n<\/li>\n<li>\nHow are IPRs handled and owned?\n<\/li>\n<li>\nWho is responsible for commercialization?\n<\/li>\n<li>\nWho is responsible for development, supply, and manufacture?\n<\/li>\n<li>\nHow is confidentiality and publication managed?\n<\/li>\n<li>\nHow are disputes to be resolved?\n<\/li>\n<li>\nUnder what conditions can the deal be terminated?\n<\/li>\n<li>\nWhat happens when there is a change of ownership?\n<\/li>\n<li>\nWhat sublicensing and subcontracting provisions have been agreed?\n<\/li>\n<li>\nWhich boilerplate clauses does the company insist upon?\n<\/li>\n<li>\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\n<\/li>\n<li>\nWhich jurisdiction does the company insist upon for agreement law?\u00a0\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>Executive Summary<\/strong>\n<\/p>\n<p>\n<strong>Chapter 1 &#8211; Introduction<\/strong>\n<\/p>\n<p>\n<strong>Chapter 2 &#8211; Trends in Cancer monoclonal antibody dealmaking<\/strong>\n<\/p>\n<p>\n2.1. Introduction\n<\/p>\n<p>\n2.2. Cancer monoclonal antibody partnering over the years\n<\/p>\n<p>\n2.3. Most active Cancer monoclonal antibody dealmakers\n<\/p>\n<p>\n2.4. Cancer monoclonal antibody partnering by deal type\n<\/p>\n<p>\n2.5. Cancer monoclonal antibody partnering by therapy area\n<\/p>\n<p>\n2.6. Deal terms for Cancer monoclonal antibody partnering\n<\/p>\n<p>\n2.6.1 Cancer monoclonal antibody partnering headline values\n<\/p>\n<p>\n2.6.2 Cancer monoclonal antibody deal upfront payments\n<\/p>\n<p>\n2.6.3 Cancer monoclonal antibody deal milestone payments\n<\/p>\n<p>\n2.6.4 Cancer monoclonal antibody royalty rates\n<\/p>\n<p>\n<strong>Chapter 3 &#8211; Leading Cancer monoclonal antibody deals<\/strong>\n<\/p>\n<p>\n3.1. Introduction\n<\/p>\n<p>\n3.2. Top Cancer monoclonal antibody deals by value\n<\/p>\n<p>\n<strong>Chapter 4 &#8211; Most active Cancer monoclonal antibody dealmakers<\/strong>\n<\/p>\n<p>\n4.1. Introduction\n<\/p>\n<p>\n4.2. Most active Cancer monoclonal antibody dealmakers\n<\/p>\n<p>\n4.3. Most active Cancer monoclonal antibody partnering company profiles\n<\/p>\n<p>\n<strong>Chapter 5 &#8211; Cancer monoclonal antibody contracts dealmaking directory<\/strong>\n<\/p>\n<p>\n5.1. Introduction\n<\/p>\n<p>\n5.2. Cancer monoclonal antibody contracts dealmaking directory\n<\/p>\n<p>\n<strong>Chapter 6 &#8211; Cancer monoclonal antibody dealmaking by technology type<\/strong>\n<\/p>\n<ul>\n<li>\nMonoclonal antibodies\n<\/li>\n<li>\nChimeric mAb\n<\/li>\n<li>\nHumanized mAb\n<\/li>\n<li>\nHuman mAb\n<\/li>\n<li>\nMurine mAb\n<\/li>\n<\/ul>\n<p>\n<strong>Appendices<\/strong>\n<\/p>\n<p>\nAppendix 1 &#8211; Cancer monoclonal antibody deals by company A-Z\n<\/p>\n<p>\nAppendix 2 &#8211; Cancer monoclonal antibody deals by stage of development\n<\/p>\n<p>\nAppendix 3 &#8211; Cancer monoclonal antibody deals by deal type\n<\/p>\n<p>\nAppendix 4 &#8211; Cancer monoclonal antibody deals by therapy area\n<\/p>\n<p>\nAppendix 5 -Deal type definitions\n<\/p>\n<p>\nAppendix 6 &#8211; Further reading on dealmaking\n<\/p>\n<p>\n<strong>Table of figures<\/strong>\n<\/p>\n<p>\nFigure 1: Therapeutic antibody definitions\n<\/p>\n<p>\nFigure 2: Cancer monoclonal antibody partnering since 2015\n<\/p>\n<p>\nFigure 3: Active Cancer monoclonal antibody dealmaking activity since 2015\n<\/p>\n<p>\nFigure 4: Cancer monoclonal antibody partnering by deal type since 2015\n<\/p>\n<p>\nFigure 5: Cancer monoclonal antibody partnering by disease type since 2015\n<\/p>\n<p>\nFigure 6: Cancer monoclonal antibody deals with a headline value\n<\/p>\n<p>\nFigure 7: Cancer monoclonal antibody deals with an upfront value\n<\/p>\n<p>\nFigure 8: Cancer monoclonal antibody deals with a milestone value\n<\/p>\n<p>\nFigure 9: Cancer monoclonal antibody deals with a royalty rate value\n<\/p>\n<p>\nFigure 10: Top Cancer monoclonal antibody deals by value since 2015\n<\/p>\n<p>\nFigure 11: Most active Cancer monoclonal antibody dealmakers since 2015\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\n3SBio\n<\/li>\n<li>\nAbpro\n<\/li>\n<li>\nAmbrx\n<\/li>\n<li>\nAmgen\n<\/li>\n<li>\nATP\n<\/li>\n<li>\nBayer\n<\/li>\n<li>\nBinex\n<\/li>\n<li>\nBiomm\n<\/li>\n<li>\nCipla\n<\/li>\n<li>\nDako\n<\/li>\n<li>\nEisai\n<\/li>\n<li>\nI-mab\n<\/li>\n<li>\nIMV\n<\/li>\n<li>\nIpsen\n<\/li>\n<li>\nIRBM\n<\/li>\n<li>\nKymab\n<\/li>\n<li>\nLonza\n<\/li>\n<li>\nMerus\n<\/li>\n<li>\nMSD\n<\/li>\n<li>\nNumab\n<\/li>\n<li>\nRoche\n<\/li>\n<li>\nTaiho\n<\/li>\n<li>\nUCB\n<\/li>\n<li>\nVIB\n<\/li>\n<li>\nWilex\n<\/li>\n<li>\nXoma\n<\/li>\n<li>\nCilag AG\n<\/li>\n<li>\nNKMax America\n<\/li>\n<li>\nViela Bio\n<\/li>\n<li>\nEssex Bio-Technology\u00a0\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/2336340\/global_cancer_monoclonal_antibody_partnering?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=rdfxbg&amp;utm_campaign=1712479+-+Global+Cancer+Monoclonal+Antibody+Partnering+Terms+and+Agreements+2015-2022%3A+Disclosed+Headlines%2C+Upfronts%2C+Milestones+and+Royalties+by+Stage+of+Development&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/pj2unt<\/a>\n<\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong>\n<\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"mail&#116;&#111;&#58;&#112;&#114;&#x65;&#x73;&#x73;&#x40;&#x72;&#x65;&#x73;earc&#104;&#97;&#110;&#100;&#109;&#x61;&#x72;&#x6b;&#x65;&#x74;&#x73;&#x2e;&#x63;om\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;e&#115;&#x73;&#64;&#x72;&#x65;&#115;&#x65;a&#114;&#x63;h&#97;&#x6e;&#100;&#x6d;a&#114;&#x6b;e&#116;&#x73;&#46;&#x63;&#x6f;&#109;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The Cancer Monoclonal Antibody Partnering Terms &amp; Agreements report provides comprehensive access to available deals and contract documents for over 600 cancer monoclonal antibody deals entered into by the worlds leading healthcare companies. This report provides details &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44992","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The Cancer Monoclonal Antibody Partnering Terms &amp; Agreements report provides comprehensive access to available deals and contract documents for over 600 cancer monoclonal antibody deals entered into by the worlds leading healthcare companies. This report provides details ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T10:01:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220613005430\/en\/1484234\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-06-13T10:01:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/\"},\"wordCount\":1332,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005430\\\/en\\\/1484234\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/\",\"name\":\"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005430\\\/en\\\/1484234\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-06-13T10:01:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005430\\\/en\\\/1484234\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005430\\\/en\\\/1484234\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The Cancer Monoclonal Antibody Partnering Terms &amp; Agreements report provides comprehensive access to available deals and contract documents for over 600 cancer monoclonal antibody deals entered into by the worlds leading healthcare companies. This report provides details ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-13T10:01:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220613005430\/en\/1484234\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development &#8211; ResearchAndMarkets.com","datePublished":"2022-06-13T10:01:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/"},"wordCount":1332,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220613005430\/en\/1484234\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/","name":"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220613005430\/en\/1484234\/21\/logo.jpg","datePublished":"2022-06-13T10:01:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220613005430\/en\/1484234\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220613005430\/en\/1484234\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2015-2022-disclosed-headlines-upfronts-milestones-and-royalties-by-stage-of-development-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44992"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44992\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}